DrugPatentWatch Database Preview

Details for Patent: 6,716,416

Which drugs does patent 6,716,416 protect, and when does it expire?

Patent 6,716,416 protects ADASUVE and is included in one NDA.

This patent has one hundred and ninety-five patent family members in nineteen countries.

Summary for Patent: 6,716,416

Title:	Delivery of antipsychotics through an inhalation route
Abstract:	The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antipsychotic; and, b) a device that forms an antipsychotic containing aerosol from the composition, for inhalation by the mammal.
Inventor(s):	Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee:	Alexza Molecular Delivery Corporation (Palo Alto, CA)
Application Number:	10/152,639
Patent Claim Types: see list of patent claims	Composition; Delivery; Use;

Drugs Protected by US Patent 6,716,416

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Galen Uk	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 6,716,416

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,070,765	Delivery of drug esters through an inhalation route	➤ Sign Up
6,716,417	Delivery on nonsteroidal antiinflammatory drugs through an inhalation route	➤ Sign Up
7,070,761	Delivery of nonsteroidal antiinflammatory drugs through an inhalation route	➤ Sign Up
6,737,042	Delivery of drug esters through an inhalation route	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 6,716,416

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	365548	➤ Sign Up
Austria	401063	➤ Sign Up
Austria	401064	➤ Sign Up
Austria	404173	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 6,716,416

For more information try a trial or see the plans and pricing